Baseline (before transfusion) differences between patients with low and high ΔHb, as well as among RBC units used in their transfusion events
| ΔHbpost-related variable . | Low . | High . | P value . | ΔHbweek-related variable . | Low . | High . | P value . |
|---|---|---|---|---|---|---|---|
| A. Patients with TDT, baseline | |||||||
| Complete blood count and biochemicals | Complete blood count and biochemicals | ||||||
| NEU, ×109/L | 6.40 ± 3.38 | 3.97 ± 1.87 | .033 | Hb, g/dL | 10.12 ± 0.84 | 9.19 ± 0.97 | .007 |
| MON, 109/L | 0.94 ± 0.57 | 0.54 ± 0.32 | .024 | HCT, % | 31.07 ± 2.65 | 28.34 ± 2.98 | .007 |
| NLR | 3.00 ± 1.63 | 1.57 ± 0.61 | .007 | PT/INR | 1.41 ± 0.58 | 1.16 ± 0.09 | .036 |
| Free protein S (% of control) | 49.1 ± 17.9 | 61.7 ± 12.5 | .029 | α2-Macroglobulin, mg/dL | 161 ± 94 | 229 ± 77 | .026 |
| VWF antigen (% of control) | 102.9 ± 44.6 | 81.9 ± 22.3 | .091 | — | — | — | — |
| RBCs and EVs | RBCs | ||||||
| PS+ RBCs, % | 1.26 ± 1.39 | 0.39 ± 0.33 | .001 | PS+ RBCs, % | 1.17 ± 1.44 | 0.52 ± 0.50 | .045 |
| EVs size, nm | 202 ± 73 | 158 ± 42 | .080 | — | — | — | — |
| Plasma metabolites | Plasma metabolites | ||||||
| Adenosine | 0.511 ± 1.241 | 0.325 ± 0.113 | .041 | 5-Oxoproline | 3.001 ± 0.606 | 3.365 ± 0.447 | .045 |
| Glycocholic acid | 2.594 ± 3.363 | 0.576 ± 0.480 | .018 | N-methyl-l-glutamic acid | 0.100 ± 0.028 | 0.079 ± 0.028 | .035 |
| L-methionine | 0.096 ±0.080 | 0.174 ±0.106 | .021 | MiNP | 0.014 ± 0.023 | 0.006 ± 0.012 | .029 |
| B. RBC units | |||||||
| Complete blood count | Complete blood count | ||||||
| PLT, 109/L | 3.68 ±2.45 | 2.2 ± 1.7 | .038 | — | — | — | — |
| RBCs and EVs | RBCs and EVs | ||||||
| PS+RBC, % | 0.25 ± 0.14 | 0.19 ± 0.16 | .066 | Oxidative hemolysis, mg/dL | 14.9 ± 11.7 | 7.5 ± 5.3 | .031 |
| TR-like PPA, RFU | 40655 ± 10182 | 48410 ± 13056 | .061 | Osmotic hemolysis, 24 hours, MCF, NaCl% | 0.506 ± 0.033 | 0.481 ± 0.034 | .051 |
| Procoagulant phospholipid activity, % | 13. 0 ± 7.0 | 7.3 ± 3.8 | .032 | CH-like PPA, m, RFU | 31349 ± 15009 | 59887 ± 37743 | .032 |
| Supernatant metabolites | Supernatant metabolites | ||||||
| Dimethyl-arginine | 4.67 ± 1.10 | 4.29 ± 1.65 | .079 | L-Arginine | 0.067± 0.108 | 0.117 ± 0.201 | .065 |
| Dopamine | 4.75 ± 2.10 | 3.81 ± 1.53 | .084 | L-Homocysteine | 0.001 ± 0.003 | 0.004 ± 0.006 | .045 |
| Norepinephrine | 1.49 ± 0.62 | 1.19 ± 0.49 | .022 | Melatonin | 1.41 ± 1.15 | 0.63 ± 0.83 | .018 |
| Normetanephrine | 31.82 ± 6.74 | 27.56 ± 7.77 | .009 | Thiamine monophosphate | 0.084 ± 0.088 | 0.139 ± 0.087 | .020 |
| Glutaryl-L-carnitine | 4.46 ± 3.14 | 2.80 ± 2.59 | .069 | Phthalic acid | 43.01 ± 28.92 | 29.58 ± 25.39 | .017 |
| 2-Amino-isobutyric acid | 0.127 ± 0.042 | 0.102 ± 0.042 | .038 | MEHP | 14.20 ± 8.76 | 10.13 ± 7.75 | .020 |
| — | — | — | — | MMP | 0.290 ± 0.474 | 0.140 ± 0.248 | .037 |
| — | — | — | — | d-Lactose | 0.298 ± 0.122 | 0.259 ± 0.204 | .037 |
| ΔHbpost-related variable . | Low . | High . | P value . | ΔHbweek-related variable . | Low . | High . | P value . |
|---|---|---|---|---|---|---|---|
| A. Patients with TDT, baseline | |||||||
| Complete blood count and biochemicals | Complete blood count and biochemicals | ||||||
| NEU, ×109/L | 6.40 ± 3.38 | 3.97 ± 1.87 | .033 | Hb, g/dL | 10.12 ± 0.84 | 9.19 ± 0.97 | .007 |
| MON, 109/L | 0.94 ± 0.57 | 0.54 ± 0.32 | .024 | HCT, % | 31.07 ± 2.65 | 28.34 ± 2.98 | .007 |
| NLR | 3.00 ± 1.63 | 1.57 ± 0.61 | .007 | PT/INR | 1.41 ± 0.58 | 1.16 ± 0.09 | .036 |
| Free protein S (% of control) | 49.1 ± 17.9 | 61.7 ± 12.5 | .029 | α2-Macroglobulin, mg/dL | 161 ± 94 | 229 ± 77 | .026 |
| VWF antigen (% of control) | 102.9 ± 44.6 | 81.9 ± 22.3 | .091 | — | — | — | — |
| RBCs and EVs | RBCs | ||||||
| PS+ RBCs, % | 1.26 ± 1.39 | 0.39 ± 0.33 | .001 | PS+ RBCs, % | 1.17 ± 1.44 | 0.52 ± 0.50 | .045 |
| EVs size, nm | 202 ± 73 | 158 ± 42 | .080 | — | — | — | — |
| Plasma metabolites | Plasma metabolites | ||||||
| Adenosine | 0.511 ± 1.241 | 0.325 ± 0.113 | .041 | 5-Oxoproline | 3.001 ± 0.606 | 3.365 ± 0.447 | .045 |
| Glycocholic acid | 2.594 ± 3.363 | 0.576 ± 0.480 | .018 | N-methyl-l-glutamic acid | 0.100 ± 0.028 | 0.079 ± 0.028 | .035 |
| L-methionine | 0.096 ±0.080 | 0.174 ±0.106 | .021 | MiNP | 0.014 ± 0.023 | 0.006 ± 0.012 | .029 |
| B. RBC units | |||||||
| Complete blood count | Complete blood count | ||||||
| PLT, 109/L | 3.68 ±2.45 | 2.2 ± 1.7 | .038 | — | — | — | — |
| RBCs and EVs | RBCs and EVs | ||||||
| PS+RBC, % | 0.25 ± 0.14 | 0.19 ± 0.16 | .066 | Oxidative hemolysis, mg/dL | 14.9 ± 11.7 | 7.5 ± 5.3 | .031 |
| TR-like PPA, RFU | 40655 ± 10182 | 48410 ± 13056 | .061 | Osmotic hemolysis, 24 hours, MCF, NaCl% | 0.506 ± 0.033 | 0.481 ± 0.034 | .051 |
| Procoagulant phospholipid activity, % | 13. 0 ± 7.0 | 7.3 ± 3.8 | .032 | CH-like PPA, m, RFU | 31349 ± 15009 | 59887 ± 37743 | .032 |
| Supernatant metabolites | Supernatant metabolites | ||||||
| Dimethyl-arginine | 4.67 ± 1.10 | 4.29 ± 1.65 | .079 | L-Arginine | 0.067± 0.108 | 0.117 ± 0.201 | .065 |
| Dopamine | 4.75 ± 2.10 | 3.81 ± 1.53 | .084 | L-Homocysteine | 0.001 ± 0.003 | 0.004 ± 0.006 | .045 |
| Norepinephrine | 1.49 ± 0.62 | 1.19 ± 0.49 | .022 | Melatonin | 1.41 ± 1.15 | 0.63 ± 0.83 | .018 |
| Normetanephrine | 31.82 ± 6.74 | 27.56 ± 7.77 | .009 | Thiamine monophosphate | 0.084 ± 0.088 | 0.139 ± 0.087 | .020 |
| Glutaryl-L-carnitine | 4.46 ± 3.14 | 2.80 ± 2.59 | .069 | Phthalic acid | 43.01 ± 28.92 | 29.58 ± 25.39 | .017 |
| 2-Amino-isobutyric acid | 0.127 ± 0.042 | 0.102 ± 0.042 | .038 | MEHP | 14.20 ± 8.76 | 10.13 ± 7.75 | .020 |
| — | — | — | — | MMP | 0.290 ± 0.474 | 0.140 ± 0.248 | .037 |
| — | — | — | — | d-Lactose | 0.298 ± 0.122 | 0.259 ± 0.204 | .037 |
Independent t test or Mann-Whitney U (2 samples) test. Metabolites: normalized values.
Bold: higher values between high- and low-ΔHb groups.
CH, chymotrypsin; INR, international normalized ratio; m; membrane; MCF, mean corpuscular fragility; MiNP, monoisononyl phthalate; MON, monocyte; NEU, neutrophil; RFU, relative fluorescence units; TR, trypsin.